Guidance to sponsors on how to manage clinical trials during the COVID-19 pandemic

Published by EMA

Clinical TrialsPandemy

The guidance provides concrete information on changes and protocol deviations which may be needed in the conduct of clinical trials to deal with extraordinary situations, e.g. if trial participants need to be in self-isolation or quarantine, access to public places (including hospitals) is limited due to the risk of spreading infections, and healthcare professionals are being reallocated

View this resource Bookmark this resource